Drug intelligence / Profile preview

ACLX-004

Development stage: Preclinical
Lead developer: Arcellx
Modality: Cell Therapies
Administration: Intravenous

Overview

ACLX-004 is an investigational cell therapy developed by Arcellx, Inc. utilizing their proprietary ARC-SparX platform. This therapy is designed to modulate both CD123 (Interleukin-3 receptor subunit alpha) and CD33 (Myeloid cell surface antigen CD33), targeting these proteins on cancer cells. ACLX-004 is being developed for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Beyond the preview

Go deeper on ACLX-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACLX-004.